23 and You? Genome research, direct-to-consumer genetics and informed consent

When US based, direct-to-consumer genetic testing company 23andMe announced last month that it had obtained a patent on a method for determining predisposition to Parkinson’s disease, it highlighted, perhaps inadvertently, a growing area of unresolved tension between clinical, commercial and research interests.


Šis įrašas paskelbtas Neklasifikuota kategorijose.

Comments are closed.